Howard Liang | Chief Financial Officer and Chief Strategy Officer |
John Oyler | Chairman, Co-Founder and Chief Executive Officer |
Xiaobin Wu | General Manager of China and President of BeiGene, Ltd. |
Eric Hedrick | Interim Chief Medical Officer, Immuno-Oncology |
Vikram Purohit | Morgan Stanley & Co. LLC |
Yaron Werber | Cowen and Company, LLC |
Ziyi Chen | Goldman Sachs & Co. |
Katherine Xu | William Blair & Company, LLC |
Tyler Van Buren | Piper Jaffray & Co. |
Wangzhi Li | Ladenburg Thalmann Financial Services |
Yige Guo | Guggenheim Partners |
Good day, ladies and gentlemen. And welcome to the Q4 2018 BeiGene Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] I would now like to introduce your host for today's conference, Dr.